Pendulum: Revolutionizing gut health through science and innovation
Pendulum: Next-generation strains to optimize metabolic health, gut health & support GLP-1 journeys*
Reimagine the health of your patients by targeting the gut microbiome
Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*
Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.*
"Pendulum combines the scientific rigor of precision therapeutics with the root-cause integrity of natural therapeutics. The next generation strains isolated by Pendulum are revolutionary for individuals looking to support gut barrier functionality and unlock metabolic potential." – Britta N., Naturopathic Doctor
.jpg%3F2025-10-07T18%3A35%3A23.016Z&w=3840&q=100)
Pendulum pioneered bringing live Akkermansia muciniphila to the market, and now it’s available to you and your patients in two dosing strengths
Akkermansia 100 Pro
Maintain keystone strain levels Regular strength live Akkermansia muciniphila helps maintain gut health, supports the gut lining, and manages gut permeability.*
Akkermansia 500 Pro
Replenish keystone strain levels Maximum strength live Akkermansia muciniphila—ideal for patients with advanced indications of intestinal barrier permeability, replenishing this critical strain for optimal gut health.§*
Get to know the products
Fullscript and Pendulum provider survey with Akkermansia 500 Pro
Will continue to recommend Akkermansia 500 Pro**
Would recommend Akkermansia 500 Pro to other health care providers**
Survey
The gut-metabolism connection: GLP-1 Probiotic supports natural GLP-1 hormone production from the gut, and supports satiety.*
In survey conducted in 2024 of healthcare providers who use a GLP-1 Probiotic
- 97% of healthcare providers recommend as a way to help manage food cravings+
- 78% Recommend as a strategy to help patients transition off of GLP-1 medications, specifically to help manage food cravings associated with this transition+
- 64% Recommend as a first line approach before prescribing a GLP-1 medication+
- 53% Recommend in combination with GLP-1 medications+
Glucose control clinical efficacy
Pendulum conducted a double-blind, placebo-controlled nutrition study that demonstrated:
- Pendulum Glucose Control’s safety for its intended use
- Glucose control has a significant statistical and clinical impact on A1c and post-meal blood sugar spikes3
- -0.6 A1c reduction
- -32.5% post prandial glucose spike reduction
Resources for your practice
Fullscript accounts are $0/month — for everyone
Get your practice and patients up and running quickly at no cost.
^Based on sales data, 2022-2025
§ Based on preclinical studies
1, 2 Based on a multicenter, double-blind, randomized placebo-controlled trial
3 Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation, Fanny Perraudeau et al, https://drc.bmj.com/content/8/1/e001319
**Survey results from 82 providers who recommended or purchased Akkermansia 500 million AFU between January-July 2024 on Fullscript.
+Based on a survey conducted internally in 2024 of 64 healthcare providers